Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Capital Expenditures (2016 - 2021)

Spero Therapeutics (SPRO) has disclosed Capital Expenditures for 6 consecutive years, with -$39000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Capital Expenditures fell 425.0% year-over-year to -$39000.0, compared with a TTM value of $24000.0 through Dec 2021, down 84.71%, and an annual FY2021 reading of -$39000.0, down 124.84% over the prior year.
  • Capital Expenditures was -$39000.0 for Q4 2021 at Spero Therapeutics, down from $12000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $129000.0 in Q4 2019 and bottomed at -$39000.0 in Q4 2021.
  • Average Capital Expenditures over 5 years is $42090.9, with a median of $32000.0 recorded in 2018.
  • The sharpest move saw Capital Expenditures skyrocketed 3300.0% in 2018, then plummeted 425.0% in 2021.
  • Year by year, Capital Expenditures stood at -$1000.0 in 2017, then surged by 3300.0% to $32000.0 in 2018, then skyrocketed by 303.12% to $129000.0 in 2019, then crashed by 90.7% to $12000.0 in 2020, then tumbled by 425.0% to -$39000.0 in 2021.
  • Business Quant data shows Capital Expenditures for SPRO at -$39000.0 in Q4 2021, $12000.0 in Q4 2020, and $51000.0 in Q3 2020.